Monitor the remaining related PGRs and IPRs on Halozyme's patent family (at least 14 other proceedings listed) — a cascade of similar invalidity findings could materially impair Halozyme's ability to enforce its PH20 hyaluronidase patent portfolio against Merck and other potential infringers. Watch for Halozyme's appeal to the Federal Circuit and any settlement developments in the parallel district court litigation.
Price Chart
Executive Summary
In a Final Written Decision, the PTAB held all challenged claims (1, 2, 6–15, 17–30) of Halozyme's U.S. Patent 12,060,590 — covering modified PH20 hyaluronidase polypeptide variants — unpatentable for lack of written description, lack of enablement, and obviousness. This patent is part of a broader patent family asserted against Merck in a pending New Jersey district court case (2:25-cv-03179) and is one of many related patents also under PTAB review. The decision removes a key patent from Halozyme's enforcement arsenal against Merck, weakening Halozyme's litigation position and potentially reducing future royalty or settlement leverage.
PTAB Trial Details
Key Facts
- PTAB Final Written Decision in PGR2025-00024 held all challenged claims (1, 2, 6–15, 17–30) of U.S. Patent 12,060,590 unpatentable on written description, enablement, and obviousness grounds.
- Patent 12,060,590 covers modified PH20 hyaluronidase polypeptides with specific amino acid modifications, including at position 307.
- The patent is asserted against Merck in Halozyme, Inc. v. Merck Sharp & Dohme LLC, 2:25-cv-03179 (D.N.J.), along with 15 other related patents.
- At least 14 other related patents are also under PTAB post-grant review at Merck's request, with many tied to the same civil action.
- The Board found that Merck failed to prove obviousness (Ground 3) but succeeded on written description and enablement (Grounds 1 and 2).
Financial Impact
Not stated in the decision. The patent is part of a multi-patent infringement suit against Merck; loss of this patent reduces potential damages and settlement value. Halozyme's revenue from ENHANZE technology platform collaborations and royalty streams may be indirectly affected if the patent family is weakened.
Risk Factors
- Further PTAB decisions on related patents may similarly invalidate additional claims, eroding Halozyme's patent protection for its PH20 technology.
- The district court case (2:25-cv-03179) may be stayed or narrowed following this decision, reducing potential damages.
- Halozyme may appeal to the Federal Circuit, but the written description and enablement findings are fact-intensive and difficult to overturn.
Investment Themes
Documents Analyzed
This report is based on 1 PTAB decision.
| Document | Accession Number |
|---|---|
| PTAB-TRIAL Data (Synthetic) | ptab-PGR2025-00024-fwd-HALO |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | Press Release | $124.54 $125.63 | ▲ +0.88% | ▲ +1.40% | $125.63 (+0.88%) |
Oct 20, 2026 5d ago | Institutional Cluster | $124.83 $124.54 | ▼ −0.23% | ▲ +0.95% | $125.63 (+0.64%) |
Oct 15, 2026 11d ago | PTAB Trial | $121.84 $122.50 | ▼ −0.54% | ▼ −0.12% | $125.63 (−3.11%) |
Oct 15, 2026 11d ago | PTAB Trial | $121.84 $122.50 | ▼ −0.54% | ▼ −0.12% | $125.63 (−3.11%) |
Sep 18, 2026 5w ago | 8-K | $112.45 $111.45 | ▼ −0.89% | ▼ −2.44% | $125.63 (+11.72%) |
Sep 17, 2026 5w ago | Insider Cluster | $112.45 $111.45 | ▼ −0.89% | ▼ −2.44% | $125.63 (+11.72%) |
Aug 19, 2026 9w ago | Insider Cluster | $106.12 $108.17 | ▲ +1.93% | ▲ +1.52% | $125.63 (+18.38%) |
Jul 9, 2026 15w ago | Insider Cluster | $76.20 $76.11 | ▼ −0.12% | ▲ +0.65% | $125.63 (+64.87%) |
Jul 2, 2026 16w ago | Insider Cluster | $80.78 $81.57 | ▲ +0.98% | ▲ +1.45% | $125.63 (+55.52%) |
Jun 3, 2026 20w ago | Insider Cluster | $71.60 $71.53 | ▼ −0.10% | ▲ +2.50% | $125.63 (+75.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time PTAB Decision Intelligence
Market-moving PTAB patent decisions analyzed within minutes. Trial institutions, denials, final written decisions, and more — parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers